Skip to content

Eastern Ablation Registry for Solid Tumor (EAST)

Eastern Ablation Registry for Solid Tumor (EAST)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03362749
Acronym
EAST
Enrollment
500
Registered
2017-12-05
Start date
2017-09-01
Completion date
2023-12-30
Last updated
2022-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor Including Thyroid, Bone, Liver, Pancreas

Brief summary

Local tumor ablation is among the major anti-tumor modalities worldwide. Given the number of changes that have taken place in the field of tumor ablation in the past 10 years, it is our intention to ensure that this highly utilized standardization continues to remain relevant as it unites all investigators and clinicians practicing interventional oncology by providing a common language to describe therapies and outcomes, develop studies, and communicate with other medical specialties. In an attempt to attain greater Asian-wide adoption, the investigators will initiate the registry system for local tumor ablation in Taiwan, China, Korea, Singapore, Hong Kong and Thailand.

Detailed description

Local tumor ablation is among the major anti-tumor modalities worldwide. Although surgical resection is potentially curative and beneficial to long-term patient survival, the majority of patients are deemed unresectable. In 2003, the International Working Group on Image-Guided Tumor Ablation published a document titled Image-Guided Tumor Ablation: Proposal for Standardization of Terms and Reporting Criteria. Ten years later, the field of tumor ablation continues to evolve. Tumor ablation modalities that were still being developed at the time of original preparation, such as microwave, irreversible electroporation (IRE), have been introduced and clinical niches are being defined. Preliminary clinical studies have matured into larger longer-term series with 5- and 10-year follow-up data on par with the surgical and medical oncology literature. Over the interim, our initial document has also given rise to several additional position statements within the field of interventional oncology and been the source for more focused societal statements on tumor ablation of liver, kidney, pancreas and musculoskeletal tumors. Given the number of changes that have taken place in the field of tumor ablation in the past 10 years, it is our intention to ensure that this highly utilized standardization continues to remain relevant as it unites all investigators and clinicians practicing interventional oncology by providing a common language to describe therapies and outcomes, develop studies, and communicate with other medical specialties. In an attempt to attain greater Asian-wide adoption, the investigators will initiate the registry system for local tumor ablation in Taiwan, China, Korea, Singapore, Hong Kong and Thailand. The main objective of the registry will be improved precision and communication in this field that leads to more accurate comparison of technologies and results and ultimately to improved patient outcomes. This study aims to establish a local tumor ablation registry in Taiwan and collect real-life data regarding the safety, efficacy, changes in clinical presentation, and practice pattern of treatment in patients with clinically confirmed solid tumor including thyroid, bone, liver, pancreas and those which are scheduated to be treated by local tumor ablation including radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation The results collected from this registry and the analyses generated will be valuable reference for physicians in choosing treatment strategy in the future.

Interventions

OTHERRFA, MWA, cryo and IRE

local tumor ablation

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who meet all inclusion criteria will be included: 1. Males or non-pregnant females, at least 18 years of age (inclusive) 2. Patients with clinically confirmed solid tumor including thyroid, bone, liver, pancreas and those which are scheduated to be treated by local tumor ablation including radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation 3. Patients who have provided written informed consent 4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 5. American Society of Anaesthesiologists (ASA) score ≤ 3

Exclusion criteria

Patients who meet any

Design outcomes

Primary

MeasureTime frameDescription
To observe the efficacy of local tumor ablationthrough study completion, an average of 1 yearResponse rate (RR) to local tumor ablation

Secondary

MeasureTime frameDescription
The effect of local tumor ablationup to 3 yearstime-to-progression
To observe the survival rateup to 3 yearsoverall survival (OS)
To observe the progression-free survival rateup to 3 yearsto observe the progression-free survival

Countries

Taiwan

Contacts

Primary ContactKai-Wen Huang, M.D. Ph.D
skywing@ntuh.gov.tw886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026